AgomAb Therapeutics NV filed for a initial public offering in the US to help fund trials of its drugs to treat immune and inflammation diseases.
The Antwerp, Belgium-based company had a net loss of $45.1 million for the nine months ended September 30, 2025, compared with a net loss of $34.5 million for the same period a year earlier, according to its filing Friday with the US Securities and Exchange Commission.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.